• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The use of CytoSorb® in a prasugrel-loaded patient undergoing emergent coronary artery bypass graft surgery.在一名服用普拉格雷的患者行急诊冠状动脉旁路移植术时使用CytoSorb®。
Clin Case Rep. 2023 Mar 19;11(3):e6990. doi: 10.1002/ccr3.6990. eCollection 2023 Mar.
2
Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.普拉格雷与氯吡格雷对未植入支架行经皮冠状动脉介入治疗的急性冠脉综合征患者预后的影响：一项通过优化血小板抑制作用评估普拉格雷改善治疗转归的试验（TRITON）-心肌梗死溶栓试验（TIMI）38亚组研究
Am Heart J. 2009 Sep;158(3):e21-6. doi: 10.1016/j.ahj.2009.06.021.
3
A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.一项关于接受经皮冠状动脉介入治疗（PCI）的急性冠状动脉综合征（ACS）患者血小板功能引导下抗血小板治疗降阶梯的随机试验。急性冠状动脉综合征慢性抗血小板治疗中血小板抑制反应性测试（TROPICAL-ACS）试验的原理与设计。
Thromb Haemost. 2017 Jan 5;117(1):188-195. doi: 10.1160/TH16-07-0557. Epub 2016 Sep 22.
4
Review of prasugrel for the secondary prevention of atherothrombosis.普拉格雷用于动脉粥样硬化血栓形成二级预防的综述。
J Manag Care Pharm. 2009 Jun;15(5):383-95. doi: 10.18553/jmcp.2009.15.5.383.
5
Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel: The ACCOAST Access Substudy.经普拉格雷治疗的非 ST 段抬高型心肌梗死患者的入路部位对出血和缺血事件的影响：ACCOAST 入路亚研究。
JACC Cardiovasc Interv. 2016 May 9;9(9):897-907. doi: 10.1016/j.jcin.2016.01.041.
6
Prasugrel increases the need for platelet transfusions and surgical reexploration rates compared with clopidogrel in coronary artery bypass surgery.与氯吡格雷相比，在冠状动脉搭桥手术中，普拉格雷会增加血小板输注需求和再次手术探查率。
Thorac Cardiovasc Surg. 2015 Feb;63(1):28-35. doi: 10.1055/s-0034-1373901. Epub 2014 May 16.
7
Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel.普拉格雷治疗的急性冠状动脉综合征患者出血的预测因素。
Heart. 2015 Aug;101(15):1219-24. doi: 10.1136/heartjnl-2015-307686. Epub 2015 Jun 9.
8
Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.普拉格雷（Efient®）联合经皮冠状动脉介入治疗急性冠状动脉综合征（TA182综述）：系统评价与经济学分析
Health Technol Assess. 2015 Apr;19(29):1-130. doi: 10.3310/hta19290.
9
Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62 737 patients with acute coronary syndromes: a nationwide registry study in Japan.在 62737 例急性冠脉综合征患者中，与标准剂量氯吡格雷相比，使用低剂量普拉格雷对经皮冠状动脉介入治疗住院结局的影响：一项日本全国注册研究。
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):231-238. doi: 10.1093/ehjcvp/pvz056.
10
Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study.在非 ST 段抬高型心肌梗死患者行经皮冠状动脉介入治疗中普拉格雷预处理策略的效果：ACCOAST-PCI 研究。
J Am Coll Cardiol. 2014 Dec 23;64(24):2563-2571. doi: 10.1016/j.jacc.2014.08.053.

本文引用的文献

1
Whole Blood Adsorber During CPB and Need for Vasoactive Treatment After Valve Surgery in Acute Endocarditis: A Randomized Controlled Study.体外循环期间全血吸附与急性心内膜炎瓣膜手术后血管活性药物治疗的需求：一项随机对照研究。
J Cardiothorac Vasc Anesth. 2022 Aug;36(8 Pt B):3015-3020. doi: 10.1053/j.jvca.2022.02.028. Epub 2022 Feb 26.
2
Rapid reduction of substantially increased myoglobin and creatine kinase levels using a hemoadsorption device (CytoSorb)-A case report.使用血液吸附装置（CytoSorb）快速降低显著升高的肌红蛋白和肌酸激酶水平——病例报告
Clin Case Rep. 2022 Jan 20;10(1):e05272. doi: 10.1002/ccr3.5272. eCollection 2022 Jan.
3
Hemoadsorption of Rivaroxaban and Ticagrelor during Acute Type A Aortic Dissection Operations.急性 A 型主动脉夹层手术期间利伐沙班和替格瑞洛的血液吸附。
Ann Thorac Cardiovasc Surg. 2022 Jun 20;28(3):186-192. doi: 10.5761/atcs.oa.21-00154. Epub 2022 Jan 20.
4
Ticagrelor Removal by CytoSorb in Patients Requiring Emergent or Urgent Cardiac Surgery: A UK-Based Cost-Utility Analysis.在需要进行急诊或紧急心脏手术的患者中，CytoSorb清除替格瑞洛的效果：一项基于英国的成本效用分析。
Pharmacoecon Open. 2020 Jun;4(2):307-319. doi: 10.1007/s41669-019-00183-w.
5
Cytosorb Adsorption During Emergency Cardiac Operations in Patients at High Risk of Bleeding.细胞吸附在高出血风险患者的紧急心脏手术中的应用。
Ann Thorac Surg. 2019 Jul;108(1):45-51. doi: 10.1016/j.athoracsur.2018.12.032. Epub 2019 Jan 23.
6
The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers.健康日本志愿者中普拉格雷和氯吡格雷的药代动力学和药效学。
Clin Pharmacol Drug Dev. 2016 Nov;5(6):480-487. doi: 10.1002/cpdd.259. Epub 2016 Apr 25.
7
Pre- and Post-Bypass Platelet Function Testing With Multiple Electrode Aggregometry and TEG Platelet Mapping in Cardiac Surgery.心脏手术中使用多电极血小板聚集仪和血栓弹力图血小板功能检测法进行体外循环前后的血小板功能测试
J Cardiothorac Vasc Anesth. 2015 Oct;29(5):1272-6. doi: 10.1053/j.jvca.2015.01.028. Epub 2015 Jan 16.
8
Pharmacokinetic basis of the antiplatelet action of prasugrel.普拉格雷抗血小板作用的药代动力学基础。
Fundam Clin Pharmacol. 2012 Feb;26(1):39-46. doi: 10.1111/j.1472-8206.2011.00986.x. Epub 2011 Sep 5.
9
Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.噻吩并吡啶P2Y12抑制剂普拉格雷的药代动力学和药效学
Pharmacotherapy. 2009 Sep;29(9):1089-102. doi: 10.1592/phco.29.9.1089.

在一名服用普拉格雷的患者行急诊冠状动脉旁路移植术时使用CytoSorb®。

The use of CytoSorb® in a prasugrel-loaded patient undergoing emergent coronary artery bypass graft surgery.

作者信息

Moresco Erich, Dejaco Hannes, Humbert Volker, Thoma Matthias

机构信息

Department of Anesthesiology and Intensive Care Medicine Medical University of Innsbruck Innsbruck Austria.

CytoSorbents Europe GmbH Berlin Germany.

出版信息

Clin Case Rep. 2023 Mar 19;11(3):e6990. doi: 10.1002/ccr3.6990. eCollection 2023 Mar.

DOI:10.1002/ccr3.6990
PMID:36950671
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10025252/
Abstract

Patients with acute coronary syndrome (ACS), failed percutaneous coronary intervention (PCI) and with an indication for emergent coronary artery bypass graft surgery (CABG) are at an increased risk of perioperative bleeding. Integration of the CytoSorb® (CS) adsorber into the cardiopulmonary bypass appears to bind prasugrel and minimize the risk of perioperative bleeding.

摘要

患有急性冠状动脉综合征（ACS）、经皮冠状动脉介入治疗（PCI）失败且有急诊冠状动脉旁路移植术（CABG）指征的患者围手术期出血风险增加。将CytoSorb®（CS）吸附器整合到体外循环中似乎能结合普拉格雷并将围手术期出血风险降至最低。